Citigroup Inc. grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 24,688.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,512 shares of the biopharmaceutical company’s stock after purchasing an additional 86,163 shares during the period. Citigroup Inc. owned approximately 0.14% of TG Therapeutics worth $870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in shares of TG Therapeutics by 152.8% in the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 26,001 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in TG Therapeutics by 44.0% in the second quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock valued at $3,658,000 after acquiring an additional 111,155 shares during the last quarter. Dupont Capital Management Corp acquired a new position in TG Therapeutics in the second quarter valued at approximately $258,000. Two Sigma Securities LLC acquired a new position in TG Therapeutics in the first quarter valued at approximately $325,000. Finally, Ameriprise Financial Inc. acquired a new position in TG Therapeutics in the first quarter valued at approximately $1,291,000. Institutional investors and hedge funds own 49.86% of the company’s stock.
TG Therapeutics, Inc. (NASDAQ TGTX) opened at 9.275 on Tuesday. TG Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.35. The stock’s market cap is $577.93 million. The company has a 50-day moving average price of $11.95 and a 200 day moving average price of $11.34.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. On average, equities research analysts predict that TG Therapeutics, Inc. will post ($1.84) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/citigroup-inc-has-870000-position-in-tg-therapeutics-inc-tgtx/1698317.html.
A number of research firms recently commented on TGTX. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. BidaskClub cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. ValuEngine cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $25.11.
TG Therapeutics Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with our FREE daily email newsletter.